Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.

Abstract

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor finding increasingly widespread use in non-Hodgkin lymphoma. Evidence of an increased risk of atrial fibrillation (AF) emerged in Phase III studies with a median incidence of approximately 6%. The mechanism remains unknown, but inhibition of a cardioprotective pathway has been proposed. Ibrutinib… (More)
DOI: 10.1080/10428194.2017.1339874

Topics

3 Figures and Tables

Slides referencing similar topics